Nucana
NCNA
Nucana (NCNA) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Oppenheimer | Maintained | Outperform | $25.00 from $150.00 | Sep 3, 2024 |
| William Blair | Downgraded | Outperform → Market Perform | — | Aug 30, 2024 |
| Oppenheimer | Maintained | Outperform | $150.00 | Aug 19, 2024 |
| Oppenheimer | Maintained | Outperform | $150.00 | Jul 23, 2024 |
| Oppenheimer | Maintained | Outperform | $150.00 from $4.00 | Jul 22, 2024 |
| Oppenheimer | Maintained | Outperform | $4.00 | Apr 1, 2024 |
| Oppenheimer | Maintained | Outperform | $4.00 | Nov 21, 2023 |
| Truist Securities | Maintained | Buy | $6.00 | Sep 6, 2023 |
| Oppenheimer | Maintained | Outperform | $4.00 | Aug 18, 2023 |
| Oppenheimer | Maintained | Outperform | $4.00 | May 22, 2023 |
Frequently asked questions
What is the latest analyst rating on NCNA?
On Sep 3, 2024, Oppenheimer maintained Nucana at Outperform with a price target of $25.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.